← Back to Clinical Trials
Recruiting NCT07361276

NCT07361276 Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care System

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07361276
Status Recruiting
Phase
Sponsor AstraZeneca
Condition Hypertension
Study Type OBSERVATIONAL
Enrollment 15,000 participants
Start Date 2026-03-31
Primary Completion 2026-07-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 15,000 participants in total. It began in 2026-03-31 with a primary completion date of 2026-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a retrospective observational cohort study based on secondary use of routinely collected electronic health data. The design was selected to enable population-level characterisation of treatment patterns and clinical inertia (both diagnostic and therapeutic) in the management of hypertension across diverse settings in Brazil's public primary care system (SUS).

Eligibility Criteria

Inclusion Criteria: * Age ≥18 years at the time of Hypertension diagnosis * Hypertension diagnosis as retrieved from registered ICD codes or CIAP Codes (primary care codes) in the EMR , OR At least two blood pressure measurements ≥140/90 mmHg during the study period. The blood measurements should be consecutive and obtained within a 30 days period. * Continuous follow-up in the same municipality for at least 6 months after index measurement. * Availability of structured EMR data including clinical encounters, diagnoses, and prescriptions Exclusion Criteria: \- Patients with incomplete data or not traceable in the registration systems

Contact & Investigator

Central Contact

AstraZeneca Clinical Study Information Center

✉ information.center@astrazeneca.com

📞 1-877-240-9479

Principal Investigator

Julia Machline Carrion, Medical

PRINCIPAL INVESTIGATOR

EpHealth Soluções em Tecnologia da Informação Ltda

Frequently Asked Questions

Who can join the NCT07361276 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07361276 currently recruiting?

Yes, NCT07361276 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.

Where is the NCT07361276 trial being conducted?

This trial is being conducted at Florianópolis, Brazil.

Who is sponsoring the NCT07361276 clinical trial?

NCT07361276 is sponsored by AstraZeneca. The principal investigator is Julia Machline Carrion, Medical at EpHealth Soluções em Tecnologia da Informação Ltda. The trial plans to enroll 15,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology